

Abstract of the Disclosure

The present invention provides a pharmaceutical composition for administering simultaneously, separately or sequentially N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof, and a HMG-CoA reductase inhibitor. The composition has an excellent lipid lowering action and excellent progress inhibitory effects on atherosclerosis, has excellent progress inhibitory effects on atherosclerosis in the aorta, has excellent onset inhibitory effects on xanthoma occurring in limb joints, and is useful as a preventive or therapeutic agent for atherosclerosis or xanthoma.

05943712-083101